{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/234878942"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Treatment strategy: Peg-IFN??-2a 180microg/week for 48 weeks, Ribavirin at least 11 mg/kg/day for 48 weeks Main inclusion criteria: HCV RNA positive by PCR; METAVIR score : >A2 and >= F1 or >= A1 and > F2; ALAT over 1.5*N; no prior treatment with IFNalpha, PEG-IFNalpha and ribavirin Main exclusion criteria : Liver disease other than hepatitis C; advanced liver disease; negative HCV RNA." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "clinicaltrials.gov" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/299679045"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/234878942"] } } }
